Skip to content

Xagenic Raises $10 million in Series A Financing

TORONTO (January 30, 2012) – Xagenic Inc., a start-up company created by Dr. Shana Kelley, in partnership with MaRS Innovation, today reached a significant milestone by successfully completing series A financing totaling $10 million.

The financing comes from sources from the private and public sector including CTI Life Sciences Fund L.P., Qiagen N.V. and the Ontario Capital Growth Corporation through its Emerging Technologies Fund.

Continue Reading

Encycle investigators receive CQDM investment

CQDM invests $1.5 million in two collaborative projects within the Québec/Ontario Life Sciences Corridor

Toronto, December 6, 2011 —  The Québec Consortium for Drug Discovery (CQDM) is pleased to announce $1.5 million in funding for two joint Québec/Ontario research projects in biomedical research.

The news was released today at the conference, Connecting Life Sciences Across the Ontario-Québec Corridor, which was held in Toronto.

Continue Reading

Prestigious Award: MaRS Innovation Board Member Ilse Treurnicht named one of Canada’s Most Powerful Women

MaRS Discovery District and MaRS Innovation congratulate CEO Dr. Ilse Treurnicht for being recognized as one of Canada’s top 100 female achievers in the private, public and not-for-profit sectors.

For a second time, Dr. Treurnicht has been honoured with the prestigious Canada’s Most Powerful Women: Top 100™. Award in the Trailblazers & Trendsetters category. Her first Top 100™ win was announced in 2009.

Continue Reading

Video: Canadian International Council interviews Rafi Hofstein about commercializing Canadian technology

Dr. Raphael Hofstein, president and CEO of MaRS Innovation, spoke to the Canadian International Council about the importance of protecting intellectual property as an important component in commercializing Canadian technologies.

Here’s an excerpt:

Government could be extremely helpful if they created special funds dedicated to covering the costs of patent protection.

Continue Reading

York University becomes 17th Member of MaRS Innovation

MaRS Innovation to act as commercialization agent for York’s life sciences and technology discoveries, leveraging new potential for York’s existing $70 million in research initiatives

TORONTO, May 9, 2011 York University has become the latest member of MaRS Innovation, the commercialization agent for many leading Toronto-based universities, hospitals and research institutes.

Stan Shapson, vice-president Research & Innovation, York University
Stan Shapson, Vice-President Research & Innovation, York University

“York has become one of Canada’s fastest-growing centres for research and innovation,” said Stan Shapson, vice-president Research & Innovation at York University. “We typically get 10 to 20 discovery disclosures a year. Joining MaRS Innovation allows us to deliver the most competitive commercialization services to the researchers making these discoveries. We’re confident that membership in MaRS Innovation will boost that number and accelerate the commercialization of York’s most promising research.”

Earlier this year, York University launched its Innovation York office. Based in York Region, Innovation York works with other partner organizations in the Markham Convergence Centre to build upon research partnerships between York researchers and life science and technology companies based in York Region and the Greater Toronto Area. It’s also making York’s research and infrastructure more accessible to industry, government agencies and community partners.

Continue Reading

Vasculotide: sanofi-aventis, Sunnybrook and MI – Article in the Globe and Mail

A discovery that could help millions of diabetics worldwide is the subject of a lucrative pharmaceutical deal that will enrich the Toronto hospital that created it – part of a growing trend of selling science to help shore up Canada’s troubled health-care system.

Tuesday’s agreement between Sanofi-Aventis and Sunnybrook Health Sciences Centre on a wound-healing molecule demonstrates how entrepreneurial hospitals can become when the very sustainability of medicare is in question.

But the licensing deal with one of the world’s biggest drug companies is also savvy medically. Until recently, some hospitals were reticent to capitalize on their discoveries, seeing commercialization as unsavoury, but now many believe it’s one of the quickest ways to get a drug to their patients.

Continue Reading
Back To Top